Prevalence of 2-year “no evidence of disease activity” (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study

Abstract

No evidence of disease activity (NEDA) is becoming a gold standard in the evaluation of disease modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS). NEDA-3 status is defined as the absence of clinical relapses, disability progression, and new/enlarging/enhancing lesions on brain MRI. NEDA-4 meets all NEDA-3 criteria plus an annualized brain volume loss (a-BVL) <0.4%. Aim of this study was to investigate the prevalence of two-year NEDA-3, NEDA-4, six-month delayed NEDA-3 (6mdNEDA-3), and six-month delayed NEDA-4 (6mdNEDA-4) in a cohort of patients with RRMS referred to an Italian tertiary MS Centre.